Roychoudhuri Lab

Great News&Views piece covering the three papers on BACH2 dosing recently published in @natimmunol.nature.com

Love the title: BACH2 the future!
www.nature.com/articles/s41...

Great News & Views piece on the three BACH2 dosing papers recently published in @natimmunol.nature.com

Love the title.. BACH2 the future!
www.nature.com/articles/s41...

Immunoinformatics is revolutionising our understanding of cancer immunology and immunotherapy responses. If anyone is interested in joining our lab through this fellowship, I'd be very keen to support an application - do get in touch! www.cancerresearch.org/immuno-infor...

A great piece in ACIR discussing the there papers on #BACH2 dosing for T cell therapy of cancer recently out in
@NatImmunol
bit.ly/3atHQyV

Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial - Nature Medicine In this randomized phase 3 trial, patients with treatment-naive stage III–IV nonsmall cell lung cancer who received sintilimab or pembrolizumab in combination with chemotherapy early in the day (befor...

Absolutely remarkable: striking effects of infusion time-of-day on immunochemotherapy efficacy in nonsmall cell lung cancer in a randomized phase 3 trial www.nature.com/articles/s41...

We have an active search for tenure-track faculty interested in #ImmuneEngineering #ProteinEngineering #GenomeEngineering & #CancerImmunology. Join the newly formed Center for Cellular Therapies and Cancer Immunology #CCTCI. Learn more at apply.interfolio.com/173562. #facultyjobs

Great to see this out, it was fun to work with Roychoudhuri lab on this really nice story. A good illustration that too much "stemness" in T cells can be a bad thing.

Unraveling CD8 lineage decisions reveals that functionally distinct CD8+ T cells are selected by different MHC-I thymic peptides @natimmunol.nature.com
www.nature.com/articles/s41...

Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy

The paper is part of three parallel submissions from the labs of Nathan Singh & Tuoqi Wu arriving at similar conclusions - that the dosage of BACH2 and the timing of its induction are key to enhancing #celltherapy for cancer.
@Cambridge_Uni @CRUKCambridge

Cancer might evade immune defences by stealing mitochondria Hijacking the energy-producing organelles from immune cells seems to help tumours in mice to infiltrate lymph nodes.

New study suggests that metastatic cancer cells may evade the immune system by stealing mitochondria from immune cells and setting up a ‘shield’ that protects them from being killed by immune cells. Wiley little bastards.

#Science 🧪

CAR NK cell therapy clinical trial puts follicular lymphoma survivor into remission   Non-Hodgkin lymphoma survivor JC Cox turned to MD Anderson when local treatment failed to keep the cancer at bay. Here, a single dose of a novel cell therapy administered through a clinical trial has put — and kept — him in remission.

"It’s exciting to think that the new therapy that helped me might be able to save other people, too," says JC Cox.

He was only the eighth person at MD Anderson to be treated with CAR NK cells. Read his story: spr.ly/63326C03Jo #OncSky #EndCancer

Terribly uncanny how relevant this is to today.

In a phase 2 trial, low-dose interleukin-2 boosted regulatory T cells and reduced arterial inflammation in acute coronary syndrome patients compared to placebo.
https://www.nature.com/articles/s41591-025-04090-y

Super cool..

Thanks Jaehyuk.. hope all is well

Wonderful to collaborate with you on this Ian and enormous thanks to Christian, Shienny and Nicole for the heavy lifting!

BACH2 dosage balances stemness & effector functions of antitumor T & CAR-T @natimmunol.nature.com @roychoudhurilab.bsky.social @ianparish.bsky.social
@washumedicine.bsky.social @utswim.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
www.nature.com/articles/s41...

Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy

Thrilled to share our latest work: Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy - now online in Nature Immunology. Led by Alberto Conti, Alex Evans and Teresa von Linde in the lab. www.nature.com/articles/s41...

Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy

The paper is part of three parallel submissions from the labs of Nathan Singh & Tuoqi Wu arriving at similar conclusions - that the dosage of BACH2 and the timing of its induction are key to enhancing #celltherapy for cancer.
@Cambridge_Uni @CRUKCambridge

Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy

Thrilled to share our latest work: Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy - now online in Nature Immunology. Led by Alberto Conti, Alex Evans and Teresa von Linde in the lab. www.nature.com/articles/s41...

Understanding How Aspirin Prevents Metastasis | NEJM A new study shows that aspirin enhances antimetastatic immunity by decreasing platelet activation, thereby releasing T cells from suppression by thromboxane A2.

Fantastic overview of mechanisms by which low-dose #Aspirin exerts prevents #metastasis in cancer www.nejm.org/doi/full/10....

📢 Don’t miss the last Cancer Biology and Medicine talk of 2025 tomorrow!

Cancer immunology and immunotherapy
Prof Rahul Roychoudhuri @campathology.bsky.social

📅 Thurs 11 December, 9:30-10:30
📍Theo Chalmers lecture theatre, School of Clinical Medicine
All welcome! @cambridge-scm.bsky.social

Catz researchers teach old drugs new tricks:

@roychoudhurilab.bsky.social (2020) on how aspirin could prevent some cancers from spreading: www.caths.cam.ac.uk/...

PhD work by Felicity Crawshay-Williams led to the identification of new combinations of existing antibiotics: www.caths.cam.ac.uk/...

We're hiring! We are looking for a Research Assistant with protein biochemistry skills to develop novel protein-based immunotherapeutics targeting Treg cells in cancer. You'll join
@roychoudhurilab.bsky.social @campathology.bsky.social @crukcamcentre.bsky.social Apply: jobs.cam.ac.uk/job/53219/

a man in a suit is holding a jacket and a cigarette . ALT: a man in a suit is holding a jacket and a cigarette .

Interesting how companies and the financial world is racing to spend mindboggling amounts of money to build the infrastructure to train computers. But we are leaving the infrastructure to train and educate humans crumbling. The question is who will train who?

A more consistently warm home, no damp on the walls in winter and much cheaper heating

Wonderful to see the seminal discoveries of Shimon Sakaguchi, Mary E. Brunkow & Fred Ramsdell recognised with the Nobel Prize. From Sakaguchi’s discovery of Treg cells to the identification of Foxp3, their research opened a new chapter in immunology, viewed from the prism of dominant tolerance.

Nuclear polarization to the immune synapse facilitates an early transcriptional burst Cytotoxic T lymphocyte target recognition triggers rapid nuclear polarization to the immune synapse and an early transcriptional burst of cytokines.

Now in #Science #Immunology: @griffithslab.bsky.social report that when #CD8 #TCells encounter their targets, #nucleus localizes to the #ImmuneSynapse (IS) & facilitates delivery of newly synthesized cytokines to the IS. They find nuclear polarization represents key step in #CTL -mediated killing!